Clinical News
2019-09-23
Molecular-matched therapy improves overall survival in pancreatic cancer
The results from the Know Your Tumor (KYT) presented at 2019 ASCO demonstrated a significant improvement in overall survival in pancreatic cancer patients with highly actionable alterations that received matched targeted therapy versus those only received
Source:
J Clin Oncol 37, 2019
2019-08-23
BLU-667 demonstrates the antitumor activity in RET fusion-positive NSCLC and other cancers
RET rearrangements have been found to promote cell proliferation in cancer, and a phase I study showed BLU-667 has antitumor activity in patients with RET fusion-positive tumor.
Source:
ASCO annual meeting 2019
2019-08-23
TAK-788 Shows Clinical Benefit in NSCLC Patients with EGFR Exon 20 Insertions
No currently approved drug can target the EGFR exon 20 insertions in NSCLC, and TAK-788 is a potential treatment for these type of patients.
Source:
J Clin Oncol 37, 2019
2019-08-23
Olaparib shows efficacy in castration-resistant prostate cancer with defects in DNA-repair genes.
The PARP inhibitor olaparib demonstrates antitumor activity in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC) with DNA damage repair gene defects.
Source:
J Clin Oncol 37, 2019
2019-08-05
Combination Immunotherapy Prolongs Overall Survival of mCRC
The results of a phase II study showed that the clinical efficacy of the combination of durvalumab and tremelimumab in patients with mCRC. Furthermore, the results indicated that bTMB can be used to select patients who benefit from immunotherapy treatment
Source:
ASCO annual meeting 2019
2019-08-05
Talazoparib Shows Clinical Benefit In PALB2-Mutated HER2-Negative Metastatic Breast Cancer Patients
Talazoparib may offer the therapeutic opportunity for HER2-negative breast cancer patients who have a non-BRCA HRR mutation, especially for those with a PALB2 mutation.
Source:
J Clin Oncol 37, 2019
2019-08-05
Ivosidenib shows clinical activity in advanced cholangiocarcinoma patients with IDH1 mutation
IDH1 is mutated in up to 25% of cholangiocarcinoma patients, and according to a phase 1 trial, ivosidenib demonstrated clinical benefit among previously treated IDH1-mutated cholangiocarcinoma patients.
Source:
Lancet Gastroenterol Hepatol. 2019
2019-07-04
STK11 and/or KEAP1 genomic alterations showed lack of clinical benefits from addition of immunotherapy to chemotherapy in NSCLC patients
A study analyzed the clinical impact of STK11 and/or KEAP1 genomic alterations in NSCLC patients received chemo-immunotherapy. The results demonstrated that the addition of immunotherapy to chemotherapy did not provide clinical benefit in patients with ST
Source:
ASCO annual meeting 2019
2019-07-04
Olaparib maintenance therapy significantly prolongs the progression-free survival of BRCA-mutated metastatic pancreatic cancer
Olaparib as maintenance therapy showed clinical benefit in prolonging progression-free survival (PFS) of pancreatic cancer who had a germline BRCA mutation in a phase III POLO study.
Source:
N Engl J Med. 2019
2019-07-04
A novel KRAS inhibitor shows promising anti-tumor activity
From a phase 1 study presented at the 2019 ASCO Annual Meeting, the KRAS G12C inhibitor AMG 510 showed encouraging anti-tumor activity in patients with KRAS G12C mutation
Source:
J Clin Oncol. 2019
